A randomized controlled trial on the treatment of COVID-19 by Qingfei Paidu Granule
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2100004673
- Lead Sponsor
- Public Health Clinical Center of Chengdu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
For the diagnosis of light and common COVID-19, refer to COVID-19 Diagnosis and Treatment Protocol (Trial Eighth Edition) (hereinafter referred to as Diagnosis and Treatment Protocol);Reference for asymptomatic infected persons: COVID-19 Control Plan (7th Edition)
1. Conform to the diagnostic criteria of mild, common COVID-19 and novel Coronavirus asymptomatic infection in the two protocols mentioned above;
2. To agree to participate in the study, the patient, legal guardian or the person in charge of the medical institution shall sign the informed consent through paper signature, mobile phone software electronic signature and voice authorization.
1. Patients who cannot guarantee medication compliance during treatment and who are difficult to administer medication through oral nasal feeding;
2. Patients with severe primary respiratory disease, or other pathogenic microbiological pneumonia that needs to be differentiated from COVID-19 or Novel Coronavirus asymptomatic infection;
3. Patients with malignant tumors, mental diseases and other systemic malignancies who are considered unsuitable for the study by the investigator;
4. People who have been allergic or intolerant to the test drug;
5. Participating in other clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method aggravation rate;duration of viral shedding;
- Secondary Outcome Measures
Name Time Method The length of time;Routine blood;Biomedical indexes;The time for temperature to normalize;Imaging CT changes;Blood biochemical;Blood oxygen saturation and oxygen absorption mode;